Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.5.0.2
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenue:        
Lymphoseek sales revenue $ 6,690,090 $ 2,952,522 $ 14,704,489 $ 6,751,492
Lymphoseek license revenue 1,295,625 550,000 1,795,625 883,333
Grant and other revenue 511,359 476,755 2,113,995 1,320,816
Total revenue 8,497,074 3,979,277 18,614,109 8,955,641
Cost of goods sold 921,817 457,590 2,017,486 1,239,377
Gross profit 7,575,257 3,521,687 16,596,623 7,716,264
Operating expenses:        
Research and development 1,276,053 3,902,155 6,461,154 10,180,517
Selling, general and administrative 2,940,773 3,942,609 9,925,574 13,485,576
Total operating expenses 4,216,826 7,844,764 16,386,728 23,666,093
Income (loss) from operations 3,358,431 (4,323,077) 209,895 (15,949,829)
Other income (expense):        
Interest expense, net (2,566,171) (2,148,369) (12,288,169) (4,690,686)
Equity in loss of R-NAV, LLC   (26,785) (15,159) (295,217)
Loss on disposal of investment in R-NAV, LLC     (39,732)  
Change in fair value of financial instruments (839,298) (1,577,275) 1,755,989 (1,702,902)
Loss on extinguishment of debt       (2,440,714)
Other, net (12,498) 4,402 (49,916) 26,100
Total other expense, net (3,417,967) (3,748,027) (10,636,987) (9,103,419)
Net income (loss) (59,536) (8,071,104) (10,427,092) (25,053,248)
Less loss attributable to noncontrolling interest (159) (340) (516) (681)
Deemed dividend on beneficial conversion feature of MT Preferred Stock       (46,000)
Net loss attributable to common stockholders $ (59,377) $ (8,070,764) $ (10,426,576) $ (25,098,567)
Loss per common share (basic and diluted) $ 0.00 $ (0.05) $ (0.07) $ (0.17)
Weighted average shares outstanding (basic and diluted) 155,481,278 150,186,131 155,390,911 150,030,638